Gonadorelin

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide (ten amino acids) produced naturally by the hypothalamus. Its role is to signal the pituitary gland, sitting at the top of the hormonal cascade that governs reproductive function.

Unlike many peptides discussed in wellness settings, gonadorelin has a long history of legitimate clinical use — as a diagnostic tool for pituitary function and in certain fertility contexts. It is also frequently discussed in testosterone-replacement (TRT) conversations as a way to keep the body's own testicular signaling active. Its behavior depends heavily on how it is administered.

Gonadorelin acts on GnRH receptors in the anterior pituitary. When it binds, the pituitary releases two gonadotropins — luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — which in turn drive the gonads (testes or ovaries).

• Stimulates the pituitary to secrete LH and FSH.
• LH and FSH then act on the gonads to support sex-hormone production and gamete development.

• The pattern of delivery is decisive: pulsatile (intermittent) exposure mimics natural GnRH release and stimulates the axis, whereas continuous exposure down-regulates GnRH receptors and suppresses it.

This pulsatile-versus-continuous distinction is a defining feature of GnRH biology and explains why the same molecule can either activate or shut down the reproductive axis depending on timing.

Gonadorelin has recognized clinical roles. Historically it has been used as a diagnostic agent to assess pituitary responsiveness, and in specific fertility settings where pulsatile GnRH delivery is used to stimulate the reproductive axis.

In TRT-related discussion, gonadorelin is often mentioned as a way to help maintain testicular function and signaling while a person is on exogenous testosterone, which otherwise suppresses the body's own LH and FSH. It is important to distinguish gonadorelin from human chorionic gonadotropin (hCG): hCG mimics LH directly at the gonad, whereas gonadorelin works one step higher up, prompting the pituitary to release its own LH and FSH.

Availability, approved indications, and regulatory status vary by region, and any use should be grounded in local regulations and clinical guidance.

Gonadorelin appears by name — in parentheses, as the synonym for GnRH itself — in sub-section S2.2.1 of the WADA Prohibited List, headed "Testosterone-stimulating peptides in males." The same bullet covers its agonist analogues (buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), and the surrounding bullets cover chorionic gonadotrophin (CG), luteinizing hormone (LH), and kisspeptin and its agonist analogues. USADA describes the underlying logic plainly: "peptide hormones and releasing factors are prohibited at all times under section S2.2 of the World Anti-Doping Agency (WADA) Prohibited List," because "the pituitary gland will secrete LH when it detects the presence of an LH-releasing factor in the blood" (USADA, peptide hormones and releasing factors).

Three points follow that are easy to get wrong:

• Prohibited in males only. The category was rewritten for the 2024 List around the effect of stimulating testosterone rather than around GnRH receptor pharmacology (USADA athlete advisory). In female athletes gonadorelin does not raise testosterone meaningfully and is not prohibited on that basis — though WADA's 2026 Monitoring Program does track "gonadotrophin-releasing hormone (GnRH) analogues in females under 18 years only," which is the usual precursor to a listing change.

• "Restoring my own hormones" is not a defence. The most common gray-market use of gonadorelin is post-cycle or on-cycle preservation of endogenous testosterone production alongside exogenous androgens. That is precisely the use S2.2.1 exists to prohibit.

• Diagnostic use is a different matter. Gonadorelin's approved role is as a short-acting diagnostic agent for pituitary gonadotropin reserve; clinically indicated use runs through the therapeutic use exemption process rather than through the prohibition.

Reported experiences include local injection-site reactions and, because gonadorelin acts on the reproductive axis, effects tied to shifts in sex-hormone signaling. Headache, nausea, and abdominal discomfort have also been described. Rare hypersensitivity reactions have been reported with GnRH agents.

Because the compound influences an entire endocrine cascade, individual response depends on context, delivery pattern, and underlying physiology, which is why medical oversight is emphasized rather than self-directed use.

Gonadorelin is a decapeptide with a short half-life, which is central to its pharmacology: natural GnRH is secreted in pulses, and the therapeutic behavior of gonadorelin tracks whether it is delivered in a pulsatile or continuous fashion. Pulsatile exposure supports the axis; continuous exposure ultimately suppresses it through receptor down-regulation.

Because the same peptide can produce opposite effects depending on delivery, this is a compound where the mechanism cannot be separated from how it is used.

Gonadorelin's formulation story has an unusual shape: the molecule is well-characterised and commercially manufactured, but almost none of that manufacturing is for humans.

Every gonadorelin product with current FDA-approved labeling in the United States is a veterinary one. Factrel Injection is approved under new animal drug application NADA 139-237 at 50 micrograms per mL and is labeled "for use in cattle only," restricted to use by or on the order of a licensed veterinarian (Factrel labeling). Cystorelin, Fertagyl, Gonabreed, and Ovacyst are the same picture under different brand names — bovine reproductive synchronisation products.

That Factrel label is also the clearest published statement of what the molecule is: it carries the identical amino-acid sequence to endogenous gonadorelin, 5-oxo-Pro-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ — ten residues, with a pyroglutamate at one end and an amide at the other, both of which slow degradation slightly but do not stop it.

In human wellness and TRT settings, gonadorelin circulates as a compounded lyophilized powder for reconstitution rather than as an approved medicine. Two older human products — Factrel as a pituitary diagnostic, and Lutrepulse (gonadorelin acetate), an intravenous pulsatile delivery system that restored ovulation in 91–96% of 109 women with hypothalamic amenorrhea in its multicentre trial (Am J Obstet Gynecol 1990) — no longer appear among currently marketed US human drug labels. Compounding supply for this axis is thin generally: in a 2022 survey of all 81 registered FDA 503B outsourcing facilities, 75 responded, and only 5 (6.67%) offered compounded hCG and 4 (5.33%) compounded FSH, with none offering compounded LH (Borgert et al., Sex Med 2023).

The pairing gonadorelin is most often discussed alongside is exogenous testosterone, and the contrast drawn is with hCG. Those are covered directly in the FAQs below rather than presented here as a regimen.

Gonadorelin and GnRH biology are well characterized in the endocrine literature. The pituitary's LH and FSH response to GnRH is well established, as is the contrast between pulsatile stimulation and continuous suppression, which underpins both fertility applications and the design of GnRH-based therapies more broadly.

Its diagnostic and fertility roles rest on decades of study, while its TRT-adjacent use is discussed more in clinical practice and community settings than in large dedicated trials. As always, high-level overviews are not a substitute for critical appraisal of primary data and current guidelines.

For deeper dives on this peptide, see:

• Gonadorelin benefits and areas of interest
• Gonadorelin side effects and safety context
• Gonadorelin dosing concepts (educational)
• Gonadorelin research and evidence overview

Is gonadorelin FDA-approved? Not for humans, in the United States, at present. Every gonadorelin product with current FDA labeling is a veterinary one — Factrel is approved under NADA 139-237 and labeled "for use in cattle only" (Factrel labeling). The human diagnostic and pulsatile-infusion products that once existed no longer appear among currently marketed US human drug labels. Gonadorelin prescribed in a US men's-health clinic is therefore a compounded preparation, which is a different regulatory category from an approved drug. In FDA's own words, "compounded drugs are not FDA-approved… FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA compounding Q&A).

How is gonadorelin different from hCG? They act at opposite ends of the same axis. Gonadorelin acts on the pituitary and asks it to release the body's own LH and FSH. hCG skips the pituitary entirely and acts at the gonad: it is a placental glycoprotein whose alpha subunit is essentially identical to that of LH and FSH, differing only in the beta subunit, and its label states directly that hCG can substitute for LH (chorionic gonadotropin labeling). Practically: gonadorelin needs a working pituitary to do anything; hCG does not. hCG also has approved human indications — prepubertal cryptorchidism, selected hypogonadotropic hypogonadism in males, and ovulation induction — which gonadorelin currently does not.

Why do pulsatile and continuous delivery have opposite effects? Because the GnRH receptor is designed to read a rhythm, not a level. The hypothalamus releases GnRH in discrete bursts, and the pituitary interprets that intermittent pattern as the "go" signal. Hold the receptor occupied continuously and it desensitises and down-regulates, and LH and FSH output collapses. This is not a quirk — it is the entire basis of the GnRH agonist drug class: triptorelin, leuprorelin, and goserelin are used to suppress sex hormones in prostate cancer and endometriosis precisely by never letting the receptor rest.

Does gonadorelin preserve testicular function on TRT? The mechanism is coherent and the human evidence is thin. Exogenous testosterone suppresses LH and FSH, and the rationale for gonadorelin is to keep prompting pituitary output so testicular signalling continues. But this use has not been established in dedicated controlled trials, and the compound has no approved human indication supporting it. Note also that hCG is described in the urology literature as the only FDA-approved therapy for hypogonadism in men desiring future fertility (Borgert et al., Sex Med 2023) — a status gonadorelin does not share.

Is gonadorelin banned in sport? Yes, in males, at all times. Gonadorelin is named in parentheses as the synonym for GnRH itself in S2.2.1 of the WADA Prohibited List, under the heading "Testosterone-stimulating peptides in males." The most common gray-market use — preserving endogenous testosterone alongside exogenous androgens — is exactly the use the category exists to prohibit, so "I was only restoring my own hormones" is not a defence.

Is gonadorelin the same as leuprolide or triptorelin? Same receptor, different molecule and very different behaviour. Gonadorelin is native GnRH, ten residues, cleared within minutes. Leuprorelin and triptorelin are modified analogues built to resist enzymatic breakdown and are formulated as long-acting depots, which produces sustained receptor occupancy and therefore suppression. Substituting one for the other is not a dose change; it is a reversal of direction.

What was gonadorelin used for clinically? Its established human role was diagnostic — a short-acting challenge to test whether the pituitary can release LH and FSH on demand, which distinguishes a pituitary problem from a hypothalamic one. Pulsatile GnRH delivered by pump was also used to induce ovulation in hypothalamic amenorrhea. Both are historical in the US market; the GnRH stimulation test itself remains in use internationally, including in diagnosing central precocious puberty in children.